New combo therapy aims to shrink high-risk rectal tumors before surgery
NCT ID NCT07505472
First seen Apr 03, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study is for people with mid-to-low rectal cancer that has high-risk features. It compares two treatment plans: short-course radiation followed by chemotherapy plus an immunotherapy drug (toripalimab), with or without an additional anti-angiogenic drug (surufatinib). The goal is to see which combination leads to a higher rate of complete tumor disappearance before surgery. About 212 adults aged 18-75 will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.